Aboxoma

Poland
Brand name Aboxoma
Form tablets, film-coated
Active substance / Dosage
apixaban · 2.5 mg
Prescription type Prescription only
ATC code
B01AF02
Registration number 100441528
Manufacturer Krka, d.d., Novo mesto

Table of Contents

Package leaflet: Information for the user

Aboxoma, 2.5 mg, coated tablets
Apixabanum
Please read all of this leaflet carefully before taking this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you personally. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in this leaflet. See section 4.

Contents of the leaflet

  1. What Aboxoma is and what it is used for
  2. What you need to know before you take Aboxoma
  3. How to take Aboxoma
  4. Possible side effects
  5. How to store Aboxoma
  6. Contents of the pack and other information

1. What Aboxoma is and what it is used for

Aboxoma contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps prevent blood clots by blocking factor Xa, an important component of the blood clotting process.
Aboxoma is used in adults:

  • to prevent blood clots (deep vein thrombosis) after hip or knee replacement surgery. After hip or knee surgery, patients have an increased risk of developing blood clots in the veins of the legs. This may lead to swelling of the legs, with or without pain. If a blood clot travels from the leg to the lungs, it may block the blood flow through the lungs, causing breathlessness with or without chest pain. This condition (pulmonary embolism) can be life-threatening and requires immediate medical attention.
  • to prevent blood clots in the heart in patients with an irregular heartbeat (atrial fibrillation) and at least one additional risk factor. Blood clots may break loose and travel to the brain, causing a stroke, or to other organs, impairing blood flow to these organs (also known as systemic embolism). A stroke can be life-threatening and requires immediate medical attention.
  • to treat blood clots in the deep veins of the legs (deep vein thrombosis) and in the blood vessels of the lungs (pulmonary embolism), and to prevent recurrence of blood clots in the blood vessels of the legs and/or lungs.

Aboxoma is used in children from 28 days to below 18 years of age, for the treatment of blood clots and prevention of recurrence of blood clots in veins or blood vessels of the lungs.
Information on body weight and recommended dose can be found in section 3.

2. Important information before using Aboxoma

When not to use Aboxoma

  • if the patient is allergic to apixaban or any of the other ingredients of this medicine (listed in section 6),
  • if the patient has active bleeding,
  • if the patient has a disease that increases the risk of serious bleeding (such as active or recently diagnosed stomach or intestinal ulcer, recently diagnosed intracranial bleeding),
  • if the patient has liver disease that leads to an increased risk of bleeding (hepatic coagulopathy),
  • if the patient is taking anticoagulant medicines (e.g. warfarin, rivaroxaban, dabigatran or heparin), except in situations of switching anticoagulant therapy, when an intravenous or arterial line has been inserted and heparin is administered through this line to maintain its patency, or when the patient is undergoing catheter ablation (a catheter is inserted into a vein) due to irregular heartbeat (arrhythmia).

Warnings and precautions
Before starting treatment, discuss with your doctor, pharmacist or nurse if the patient has any of the following conditions:

  • increased risk of bleeding, for example:
  • conditions associated with bleeding, including those resulting in reduced platelet function,
  • very high blood pressure not controlled with medication,
  • if the patient is over 75 years of age,
  • if the patient weighs 60 kg or less,
  • severe kidney disease or if the patient is on dialysis,
  • liver disease or history of liver disease.
  • Aboxoma should be used with caution in patients showing signs of impaired liver function.
  • a spinal catheter or spinal injection (anaesthetic or pain relief), in which case the doctor will advise taking Aboxoma 5 or more hours after removal of the catheter,
  • if the patient has a heart valve prosthesis,
  • if the doctor determines that the patient's blood pressure is unstable or other treatment or a surgical procedure to remove a blood clot from the lungs is planned.

When to exercise particular caution when using Aboxoma
If the patient has a disorder called antiphospholipid syndrome (an autoimmune disorder causing increased risk of blood clots), the patient should inform their doctor, who will decide whether a change in treatment is necessary.
If the patient needs to undergo surgery or a procedure that may involve bleeding, the doctor may ask the patient to temporarily stop taking this medicine for a short period. If in doubt whether a procedure may involve bleeding, ask the doctor.

Children and adolescents
Use of this medicine is not recommended in children and adolescents with body weight below 35 kg.

Aboxoma and other medicines
Tell your doctor, pharmacist or nurse about all medicines the patient is currently taking, has recently taken or plans to take.
Some medicines may enhance the effect of Aboxoma, while others may reduce its effect. The doctor will decide whether the patient should receive Aboxoma while taking other medicines and how closely they should be monitored.

The following medicines may enhance the effect of Aboxoma and increase the risk of unwanted bleeding:

  • certain medicines used to treat fungal infections (e.g. ketoconazole and others);
  • certain antiviral medicines used to treat HIV/AIDS infection (e.g. ritonavir);
  • other medicines used to reduce blood clotting (e.g. enoxaparin and others);
  • anti-inflammatory or pain-relieving medicines (e.g. acetylsalicylic acid or naproxen); particularly if the patient is over 75 years of age and taking acetylsalicylic acid, they may be at increased risk of unwanted bleeding;
  • medicines used for high blood pressure or heart disease (e.g. diltiazem);
  • antidepressant medicines known as selective serotonin reuptake inhibitors (SSRIs) or serotonin-noradrenaline reuptake inhibitors (SNRIs).

The following medicines may reduce the ability of Aboxoma to prevent blood clots:

  • medicines used to prevent seizures or convulsions (e.g. phenytoin and others);
  • St. John's wort (an herbal supplement used for depression);
  • medicines used to treat tuberculosis or other infections (e.g. rifampicin).

Pregnancy and breastfeeding
If the patient is pregnant or breastfeeding, suspects she may be pregnant, or is planning to have a child, she should consult her doctor, pharmacist or nurse before using this medicine.
The effect of Aboxoma on pregnancy and the unborn child is unknown. Aboxoma should not be used during pregnancy. If the patient becomes pregnant while taking Aboxoma, she should contact her doctor immediately.
It is not known whether Aboxoma passes into breast milk. The patient should consult her doctor, pharmacist or nurse before using this medicine while breastfeeding.
The patient may be advised to stop breastfeeding or to avoid starting this medicine.

Driving and using machines
Apixaban has no effect or a negligible effect on the ability to drive and operate machinery.

Aboxoma contains lactose and sodium
If the patient has been diagnosed with an intolerance to certain sugars, consult a doctor before taking this medicine.
The medicine contains less than 1 mmol of sodium (23 mg) per tablet; therefore, this medicine is considered "sodium-free".

3. How to take Aboxoma

This medicine should always be taken exactly as instructed by your doctor or pharmacist. If you are unsure,
please consult your doctor, pharmacist, or nurse.
Dosage
The tablet should be swallowed with water. Aboxoma can be taken with or without food.
To achieve the best treatment results, it is recommended to take the tablets at the same times each day.
If a patient has difficulty swallowing the tablets whole, they should speak with their doctor about alternative
ways of taking Aboxoma. The tablet may be crushed immediately before administration and mixed with water or 5% aqueous glucose solution, juice, or apple puree.
Instructions for crushing tablets:

  • Crush the tablet with a pestle in a mortar.
  • Carefully transfer the powder into a suitable container and mix it with a small amount, e.g., 30 mL (2 tablespoons), of water or another liquid mentioned above to prepare a mixture.
  • Swallow the mixture.
  • Rinse the pestle and mortar used for crushing the tablets, as well as the container, with a small amount of water or another liquid (e.g., 30 mL), and swallow the rinse liquid.

If necessary, your doctor may administer crushed Aboxoma tablets mixed with 60 mL of water or 5% aqueous glucose solution via a nasogastric tube.
Aboxoma should be taken as instructed for the following indications:
Prevention of blood clots after hip or knee replacement surgery
The recommended dose is one 2.5 mg Aboxoma tablet twice daily, for example, one tablet in the morning and one in the evening.
The first tablet should be taken 12 to 24 hours after surgery.
If the patient underwent major hip surgery, they will usually take the tablets for 32 to 38 days.
If the patient underwent major knee surgery, they will usually take the tablets for 10 to 14 days.
Prevention of blood clots in the heart in patients with irregular heart rhythm and at least one additional risk factor
The recommended dose is one 5 mg Aboxoma tablet twice daily.
The recommended dose is one 2.5 mg Aboxoma tablet twice daily if:

  • the patient has severe renal impairment,
  • two or more of the following conditions are met:
  • blood test results suggest impaired kidney function (serum creatinine level ≥1.5 mg/dL (133 micromoles/L)),
  • the patient is 80 years of age or older,
  • the patient’s body weight is 60 kg or less.

The recommended dose is one tablet twice daily, for example, one tablet in the morning and one in the evening. Your doctor will decide how long treatment should continue.
Treatment of blood clots in the deep veins of the legs and blood clots in the blood vessels of the lungs
The recommended dose is two 5 mg Aboxoma tablets twice daily for the first 7 days, for example, two tablets in the morning and two in the evening.
After 7 days, the recommended dose is one 5 mg Aboxoma tablet twice daily, for example, one tablet in the morning and one in the evening.
Prevention of recurrence of blood clots after completion of 6-month treatment
The recommended dose is one 2.5 mg Aboxoma tablet twice daily, for example, one tablet in the morning and one in the evening.
Your doctor will decide how long treatment should continue.
Use in children and adolescents
Treatment of blood clots and prevention of recurrence of blood clots in veins or in the blood vessels of the lungs.
This medicine should always be taken or administered exactly as instructed by your doctor or pharmacist.
If you are unsure, please consult your doctor, pharmacist, or nurse.
To achieve the best treatment effect, the dose should be taken or administered at the same time each day.
The apixaban dose is based on body weight and will be calculated by the doctor.
The recommended dose for children and adolescents weighing at least 35 kg is four 2.5 mg Aboxoma tablets, taken twice daily for the first 7 days, for example, four in the morning and four in the evening. After 7 days, the recommended dose is two 2.5 mg Aboxoma tablets, taken twice daily, for example, two in the morning and two in the evening.
For parents and caregivers: observe the child to ensure the full dose has been taken.
It is important to attend scheduled doctor visits, as changes in body weight may require dose adjustment.
Your doctor may change anticoagulant treatment as follows:

  • Switching from Aboxoma to other anticoagulant medicines Discontinue Aboxoma. Start treatment with anticoagulant medicines (e.g., heparin) at the time the next tablet was scheduled to be taken.
  • Switching from anticoagulant medicines to Aboxoma Discontinue anticoagulant medicines. Start Aboxoma treatment at the time the next dose of anticoagulant medicine was scheduled, and continue regular dosing thereafter.
  • Switching from anticoagulant treatment including a vitamin K antagonist (e.g., warfarin) to Aboxoma Discontinue the vitamin K antagonist-containing medicine. Your doctor must perform blood tests and will inform you when to start taking Aboxoma.
  • Switching from Aboxoma to anticoagulant treatment including a vitamin K antagonist (e.g., warfarin) If your doctor informs you that you should start taking a vitamin K antagonist-containing medicine, continue taking Aboxoma for at least 2 days after taking the first dose of the vitamin K antagonist-containing medicine. Your doctor must perform blood tests and will inform you when to stop taking Aboxoma. Patients undergoing cardioversion Patients who require cardioversion to restore normal heart rhythm should take this medicine at the times specified by their doctor to prevent blood clots in the brain's blood vessels and other blood vessels in the body.

Taking more Aboxoma than recommended
If you have taken more Aboxoma than recommended, contact your doctor immediately. Bring the medicine packaging with you, even if it is empty.
If you have taken more Aboxoma than recommended, your risk of bleeding may increase. In case of bleeding, surgical treatment, blood transfusion, or other treatment to reverse the anti-factor Xa effect may be necessary.
Missing a dose of Aboxoma

  • If you miss a morning dose, take it as soon as you remember, and you may take it at the same time as your evening dose.
  • A missed evening dose may only be taken on the same evening. Do not take two doses the next morning; instead, continue taking the medicine the next day as recommended, twice daily.

If you have any doubts about using the medicine or if you miss more than one dose, consult your doctor, pharmacist, or nurse.
Stopping Aboxoma
Do not stop taking Aboxoma without consulting your doctor, as stopping this medicine prematurely may increase the risk of developing a blood clot.
If you have any further questions about using this medicine, consult your doctor, pharmacist, or nurse.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone will experience them.
Aboxoma can be used for three different medical conditions. The known adverse reactions and their frequency of occurrence in each of these medical conditions may differ and are listed separately below. In these conditions, the most common general adverse reaction associated with this medicine is bleeding, which may potentially be life-threatening and may require immediate medical attention.

The following adverse reactions may occur when Aboxoma is used to prevent blood clots after hip or knee surgery.

Common adverse reactions (may occur in up to 1 in 10 people)

  • Anaemia, which may cause fatigue or paleness;
  • Bleeding including:
    • Bruising and swelling;
  • Nausea.

Uncommon adverse reactions (may occur in up to 1 in 100 people)

  • Decreased number of platelets (which may affect blood clotting);
  • Bleeding:
    • After surgery, including bruising and swelling, leakage of blood or other fluid from the surgical wound or incision site (wound discharge) or at the injection site;
    • From the stomach, intestines, or bright red blood in stool;
    • Blood in urine;
    • Nosebleeds;
    • From the genital tract;
  • Low blood pressure, which may lead to fainting or rapid heartbeat;
  • Blood test results may indicate:
    • Liver function abnormalities;
    • Increased activity of certain liver enzymes;
    • Increased bilirubin levels—a breakdown product of destroyed red blood cells that may cause yellowing of the skin and eyes;
  • Itching.

Rare adverse reactions (may occur in up to 1 in 1000 people)

  • Allergic (hypersensitivity) reactions, which may cause: swelling of the face, lips, mouth, tongue and (or) throat, and breathing difficulties. If any of these symptoms occur, seek immediate medical advice;
  • Bleeding:
    • Into muscle tissue;
    • Into the eyes;
    • From gums and coughing up blood;
    • From the rectum;
  • Hair loss.

Frequency not known (cannot be estimated from available data)

  • Bleeding:
    • Into the brain or spinal canal;
    • In the lungs or throat;
    • In the mouth;
    • Into the abdominal cavity or retroperitoneal space;
    • From haemorrhoids;
  • Test results indicating presence of blood in stool or urine;
  • Skin rash, sometimes with blister formation, resembling small target-like lesions (dark spots in the center surrounded by a lighter ring, with a dark ring at the edge) (erythema multiforme);
  • Vasculitis (inflammation of blood vessels), which may cause skin rash or raised, flat, red, circular spots beneath the skin surface, or bruising;
  • Bleeding in the kidney, sometimes with blood in urine, leading to impaired kidney function (anticoagulant-associated nephropathy).

The following adverse reactions may occur when Aboxoma is used to prevent blood clots in the heart in patients with irregular heart rhythm and at least one additional risk factor.

Common adverse reactions (may occur in up to 1 in 10 people)

  • Bleeding, including:
    • Into the eye;
    • Into the stomach or intestine;
    • From the rectum;
    • Blood in urine;
    • Nosebleeds;
    • From gums;
    • Bruising and swelling;
  • Anaemia, which may cause fatigue or paleness;
  • Low blood pressure, which may lead to fainting or rapid heartbeat;
  • Nausea;
  • Blood test results may indicate:
    • Increased gamma-glutamyltransferase (GGT) activity.

Uncommon adverse reactions (may occur in up to 1 in 100 people)

  • Bleeding:
    • Into the brain or spinal canal;
    • In the mouth or coughing up blood;
    • Into the abdominal cavity or from the genital tract;
    • Bright red blood in stool;
    • Postoperative bleeding, including bruising and swelling, leakage of blood or fluid from the surgical wound or incision site (wound discharge) or at the injection site;
    • From haemorrhoids;
    • Presence of blood in stool or urine detected in laboratory tests;
  • Decreased platelet count (which may affect clotting);
  • Blood test results may indicate:
    • Abnormal liver function;
    • Increased activity of certain liver enzymes;
    • Increased bilirubin levels—a breakdown product of red blood cells that may cause yellowing of the skin and eyes;
  • Skin rash;
  • Itching;
  • Hair loss;
  • Allergic (hypersensitivity) reactions, which may cause: swelling of the face, lips, mouth, tongue and (or) throat, and breathing difficulties. If any of these symptoms occur, seek immediate medical advice.

Rare adverse reactions (may occur in up to 1 in 1000 people)

  • Bleeding:
    • In the lungs or throat;
    • Into the retroperitoneal space;
    • Into muscle tissue.

Very rare adverse reactions (may occur in up to 1 in 10,000 people)

  • Skin rash, sometimes with blister formation, resembling small target-like lesions (dark spots in the center surrounded by a lighter ring, with a dark ring at the edge) (erythema multiforme).

Frequency not known (cannot be estimated from available data)

  • Vasculitis (inflammation of blood vessels), which may cause skin rash or raised, flat, red, circular spots beneath the skin surface, or bruising;
  • Bleeding in the kidney, sometimes with blood in urine, leading to impaired kidney function (anticoagulant-associated nephropathy).

The following adverse reactions may occur when Aboxoma is used to treat or prevent recurrence of blood clots in the veins of the legs and in blood vessels of the lungs.

Common adverse reactions (may occur in up to 1 in 10 people)

  • Bleeding, including:
    • Nosebleeds;
    • From gums;
    • Blood in urine;
    • Bruising and swelling;
    • In the stomach, intestines, or from the rectum;
    • In the mouth;
    • From the genital tract;
  • Anaemia, which may cause fatigue or paleness;
  • Decreased platelet count (which may affect clotting);
  • Nausea;
  • Skin rash;
  • Blood test results may indicate:
    • Increased gamma-glutamyltransferase (GGT) or alanine aminotransferase (AlAT) activity.

Uncommon adverse reactions (may occur in up to 1 in 100 people)

  • Low blood pressure, which may lead to fainting or rapid heartbeat;
  • Bleeding:
    • Into the eyes;
    • In the mouth or coughing up blood;
    • Bright red blood in stool;
    • Test results indicating blood in stool or urine;
    • Postoperative bleeding, including bruising and swelling, leakage of blood or fluid from the surgical wound or incision site (wound discharge) or at the injection site;
    • From haemorrhoids;
    • Into muscle tissue;
  • Itching;
  • Hair loss;
  • Allergic (hypersensitivity) reactions, which may cause: swelling of the face, lips, mouth, tongue and (or) throat, and breathing difficulties. If any of these symptoms occur, seek immediate medical advice;
  • Blood test results may indicate:
    • Abnormal liver function;
    • Increased activity of certain liver enzymes;
    • Increased bilirubin levels—a breakdown product of red blood cells that may cause yellowing of the skin and eyes.

Rare adverse reactions (may occur in up to 1 in 1000 people)

  • Bleeding:
    • Into the brain or spinal canal;
    • In the lungs.

Frequency not known (cannot be estimated from available data)

  • Bleeding:
    • Into the abdominal cavity or retroperitoneal space.
  • Skin rash, sometimes with blister formation, resembling small target-like lesions (dark spots in the center surrounded by a lighter ring, with a dark ring at the edge) (erythema multiforme);
  • Vasculitis (inflammation of blood vessels), which may cause skin rash or raised, flat, red, circular spots beneath the skin surface, or bruising;
  • Bleeding in the kidney, sometimes with blood in urine, leading to impaired kidney function (anticoagulant-associated nephropathy).

Additional adverse reactions in children and adolescents
If any of the following symptoms occur, seek immediate medical advice:

  • Allergic (hypersensitivity) reactions, which may cause: swelling of the face, lips, mouth, tongue and (or) throat, and breathing difficulties. The frequency of these adverse reactions is classified as "common" (may occur in up to 1 in 10 people).

In general, adverse reactions observed in children and adolescents treated with Aboxoma were similar to those seen in adults and were mostly mild or moderate in severity. Adverse reactions occurring more frequently in children and adolescents include nosebleeds and abnormal vaginal bleeding.

Very common adverse reactions (may occur in more than 1 in 10 people)

  • Bleeding, including:
    • From the vagina;
    • Nosebleeds.

Common adverse reactions (may occur in up to 1 in 10 people)

  • Bleeding, including:
    • From gums;
    • Blood in urine;
    • Bruising (ecchymoses) and swelling;
    • From the intestine or rectum;
    • Bright red blood in stool;
    • Postoperative bleeding, including bruising (ecchymoses) and swelling, leakage of blood (discharge) from the surgical wound or injection site;
  • Hair loss;
  • Anaemia, which may cause fatigue or paleness;
  • Decreased platelet count (which may affect coagulability);
  • Nausea;
  • Skin rash;
  • Itching;
  • Low blood pressure, which may cause fainting or rapid heartbeat;
  • Blood test results may indicate:
    • Abnormal liver function;
    • Increased activity of certain liver enzymes;
    • Increased alanine aminotransferase (ALT) activity.

Frequency not known (cannot be estimated from available data)

  • Bleeding:
    • Into the abdominal cavity or retroperitoneal space;
    • In the stomach;
    • In the eyes;
    • In the mouth;
    • From haemorrhoids;
    • In the mouth or blood in sputum when coughing;
    • Into the brain or spine;
    • In the lungs;
    • In muscle;
  • Skin rash, sometimes with blister formation, resembling small target-like lesions (dark spots in the center surrounded by a lighter ring, with a dark ring at the edge) (erythema multiforme);
  • Vasculitis, which may cause skin rash or raised, flat, red, circular spots beneath the skin surface or bruising;
  • Blood test results may indicate:
    • Increased gamma-glutamyltransferase (GGT) activity;
    • Presence of blood in faeces or urine;
  • Bleeding in the kidney, sometimes with blood in urine, leading to impaired kidney function (anticoagulant-associated nephropathy).

Reporting of adverse reactions
If any adverse reactions occur, including any not listed in this leaflet, inform your doctor or pharmacist. Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions at the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products:
Al. Jerozolimskie 181C, 02-222 Warsaw
Tel.: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the marketing authorization holder.
Reporting adverse reactions helps provide more information on the safety of this medicine.

5. How to store Aboxoma

Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging after the abbreviation
EXP. The expiry date refers to the last day of the stated month.
No special storage conditions are required.
Medicines should not be disposed of via wastewater or household waste. Ask your
pharmacist how to dispose of medicines no longer in use. This will help protect
the environment.

6. Contents of the pack and other information

What Aboxoma contains

  • The active substance is apixaban. Each coated tablet contains 2.5 mg of apixaban.
  • The other ingredients (excipients) are: microcrystalline cellulose (E 460), lactose monohydrate, sodium croscarmellose (E 468), sodium lauryl sulphate, hydroxyethylcellulose, magnesium stearate (E 470b) in the tablet core, and hypromellose (E 464), propylene glycol (E 1520), titanium dioxide (E 171) and talc (E 553b) in the coating. See section 2, "Aboxoma contains lactose and sodium".

What Aboxoma looks like and contents of the pack
White, round, biconvex coated tablets (tablets) marked with the number 2.5 on one side of the tablet.
Tablet dimensions: approximately 6 mm in diameter.
Aboxoma is available in packs containing:

  • 20, 56 or 60 coated tablets. Not all pack sizes may be marketed.

Patient Card: information for use
Inside the Aboxoma packaging, together with the patient leaflet, a Patient Card is included, or your physician may provide you with a similar card.
The Patient Card contains helpful information for the patient and alerts other physicians that the patient is taking Aboxoma. You should always carry this card with you.

  1. Take the card.
  2. If necessary, separate the appropriate language section (this is facilitated by perforated edges).
  3. Complete the following sections, or ask your doctor to complete them:
    • Name:
    • Date of birth:
    • Indication:
    • Body weight (for children and adolescents):
    • Dose: … mg twice daily
    • Doctor's name:
    • Doctor's telephone number:
  4. Fold the card and always carry it with you.

Marketing Authorisation Holder and Manufacturer
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
For further information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
KRKA-POLSKA Sp. z o.o.
ul. Równoległa 5
02-235 Warsaw, Poland
Tel. 22 57 37 500